Henry Schein, Inc. (HSIC) Receives Consensus Recommendation of “Hold” from Analysts
Henry Schein, Inc. (NASDAQ:HSIC) has been assigned a consensus rating of “Hold” from the eighteen brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $184.64.
Several research firms have weighed in on HSIC. Jefferies Group LLC reissued a “hold” rating and issued a $177.00 target price on shares of Henry Schein in a research note on Friday, July 21st. Zacks Investment Research raised Henry Schein from a “hold” rating to a “buy” rating and set a $190.00 price target on the stock in a research report on Tuesday, April 25th. Stifel Nicolaus reaffirmed a “hold” rating on shares of Henry Schein in a research report on Thursday, July 6th. Barrington Research raised their price target on Henry Schein from $196.00 to $198.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 10th. Finally, Northcoast Research raised Henry Schein from a “neutral” rating to a “buy” rating and set a $218.00 price target on the stock in a research report on Monday, August 7th.
Shares of Henry Schein (HSIC) opened at 170.82 on Tuesday. The firm has a market cap of $13.50 billion, a P/E ratio of 24.96 and a beta of 1.09. The firm’s 50-day moving average price is $179.14 and its 200 day moving average price is $175.79. Henry Schein has a 12-month low of $146.23 and a 12-month high of $186.99. Shares of Henry Schein are scheduled to split on the morning of Friday, September 15th. The 2-1 split was announced on Wednesday, August 16th. The newly created shares will be payable to shareholders after the market closes on Thursday, September 14th.
Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 8th. The company reported $1.75 earnings per share for the quarter, beating the consensus estimate of $1.73 by $0.02. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The firm had revenue of $3.06 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the prior year, the firm posted $1.64 earnings per share. The company’s quarterly revenue was up 6.4% on a year-over-year basis. On average, equities analysts expect that Henry Schein will post $7.27 earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in the stock. YorkBridge Wealth Partners LLC raised its stake in shares of Henry Schein by 5.2% in the second quarter. YorkBridge Wealth Partners LLC now owns 570 shares of the company’s stock worth $104,000 after buying an additional 28 shares in the last quarter. Sun Life Financial INC raised its stake in shares of Henry Schein by 8,185.7% in the second quarter. Sun Life Financial INC now owns 580 shares of the company’s stock worth $106,000 after buying an additional 573 shares in the last quarter. SpiderRock Advisors LLC purchased a new stake in shares of Henry Schein during the first quarter worth about $102,000. Lee Financial Co purchased a new stake in shares of Henry Schein during the second quarter worth about $161,000. Finally, JNBA Financial Advisors purchased a new stake in shares of Henry Schein during the first quarter worth about $170,000. 90.60% of the stock is currently owned by institutional investors and hedge funds.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.